Ligand Pharmaceuticals Incorporated — FY 2014 Form 10-K
Business context and reporting period. This annual report covers the year ended December 31, 2014; it is not a standalone quarterly filing. Ligand develops and acquires partnered drug and technology assets, earning primarily royalties, Captisol material sales, license fees and milestones while partners generally fund development and commercialization. Approximately 43% of 2014 revenue came from Promacta and Kyprolis royalties, and approximately 44% from Captisol sales.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $64.5 million | $49.0 million |
| Royalties | $30.0 million | $23.6 million |
| Captisol material sales | $28.5 million | $19.1 million |
| Collaborative and other revenue | $6.1 million | $6.3 million |
| Operating income | $19.6 million | $14.9 million |
| Income from continuing operations | $12.0 million | $8.8 million |
| Net income | $12.0 million | $11.4 million |
| Operating cash flow | $20.6 million | $20.7 million |
| Cash and cash equivalents | $160.2 million | $11.6 million |
| Working capital | $162.4 million | $(4.1) million |
Revenue increased approximately 32% year over year, driven mainly by higher royalties and Captisol demand. Based on reported figures, operating margin was approximately 30% and net margin approximately 19%. Captisol sales gross margin was approximately 68%, calculated from reported sales and cost of material sales. Q4 2014 revenue was $23.0 million and net income was $7.1 million.
Operating cash flow was nearly flat year over year; the 2014 result included a $10.4 million increase in accounts receivable and $11.3 million of noncash stock-based compensation. Investing activities used $2.0 million; financing activities provided $130.0 million, principally reflecting convertible-note proceeds, offset by share repurchases, debt repayment and the convertible bond hedge.
Ligand issued $245.0 million principal amount of 0.75% convertible notes due 2019; the balance-sheet carrying amount was $195.9 million after discount. The company repaid its prior term loan in July 2014. Total assets were $258.0 million and total liabilities $233.6 million at year-end. Cash, cash equivalents and short-term investments totaled approximately $167.3 million, excluding restricted cash.
Material changes and business developments
- Promacta and Kyprolis royalties rose, while Captisol sales increased with greater clinical and commercial demand. Two customers accounted for 64% of year-end accounts receivable; three partners each represented at least 10% of revenue, with shares of 37%, 31% and 10% (partners not identified in that disclosure).
- Captisol-enabled Noxafil-IV received FDA, EMA and Health Canada approval; Ligand earns Captisol sales revenue, not royalties, on the program.
- Promacta received U.S. approval for severe aplastic anemia in 2014. Pediatric ITP submissions and further indications were in development or review. GSK’s planned transfer of the franchise to Novartis was expected to complete in the first half of 2015, subject to regulatory review.
- Ligand’s late-stage portfolio included Spectrum’s Captisol-enabled melphalan NDA under FDA review and Lundbeck’s carbamazepine-IV NDA, which received an FDA Complete Response Letter requesting CMC information. Other partnered programs included Merck’s Phase 3 Alzheimer’s candidate and Phase 3 delafloxacin development.
- Ligand repurchased approximately 1.25 million shares for $68.0 million in 2014. It had authorization for up to $200 million of repurchases, subject to market conditions and other factors.
Outlook, risks and unusual items
Management said available cash, investments, royalties and Captisol sales were expected to fund operating and capital needs at least through December 31, 2015, and anticipated increasing operating cash flow and building cash. The filing provides no specific revenue or earnings guidance. Management cautioned that revenue, partner activity, approvals and development progress may differ materially from expectations.
- Revenue is materially dependent on Promacta, Kyprolis and Captisol. Captisol is sourced from a single supplier, Hovione; supply interruption could disrupt sales. Required Captisol purchase commitments were $15.4 million.
- Generic Avinza launched in February 2014. Ligand expected Avinza royalties to stop in Q2 2015 and remaining payments to be minimal; Pfizer had stopped selling the product to wholesalers.
- Ligand consolidated Viking as a variable-interest entity despite holding no equity interest. It extended a $2.5 million convertible loan and disclosed uncertainty about repayment and Viking’s financing; Ligand could terminate the license agreement on or after April 30, 2015 if funding conditions were not met.
- Interest expense rose to $4.9 million, partly from the convertible notes’ discount amortization. A $5.1 million increase in contingent-liability fair value was also recorded as expense. Stock-based compensation rose to $11.3 million from $5.7 million.
- A securities lawsuit naming Ligand and its CEO was revived on appeal; the outcome was described as not presently determinable. A separate executive-compensation-related case had a settlement agreement, with dismissal pending and material loss considered remote.
- Other key risks include clinical and regulatory failure or delay, partner termination or underinvestment, patent challenges and generic competition, product liability and legacy indemnification exposure, and possible limitations on use of tax-loss carryforwards. The company reported a full valuation allowance against deferred tax assets.
The independent auditor issued an unqualified opinion on the financial statements and internal controls. Management and the auditor concluded internal control over financial reporting was effective at December 31, 2014.
Important facts for investors to verify
- How much of future revenue and cash generation depends on continued Promacta and Kyprolis growth and Captisol demand, and how concentrated those revenues are among partners.
- Progress and commercial potential of the melphalan, carbamazepine-IV, pediatric Promacta and other pipeline programs, including regulatory outcomes and partner commitments.
- Cash conversion and receivables: operating cash flow was below net income, while accounts receivable increased materially.
- Convertible-note repayment and dilution terms, including the $75.05 initial conversion price, $125.08 warrant exercise price and cash settlement obligations.
- Hovione supply continuity, $15.4 million purchase commitments, contingent-value-right obligations and the outcome of the securities litigation.